Biopsies have been used since 1951 and are still considered the gold standard for assessing kidney graft status. In many transplant programs patients are periodically subjected to these invasive procedures every so often as part of a surveillance program (so called “surveillance” or “protocol” biopsies) to help clinicians determine whether a patient is silently rejecting, with no test results indicating any problem, or if their immune system is truly adequately suppressed. This is done because studies have shown that as many as 25% of patients who appear to be just fine have actually begun to reject but existing non-invasive tests are too insensitive to detect it. However, 75% of all surveillance biopsies show no signs of kidney damage or rejection while subjecting stable patients to pain, inconvenience and risk of complications – possibly even graft loss. It’s time for a better solution.

TruGraf is the first non-invasive blood test clinicians can use to help assess whether their patients are adequately immunosuppressed, prior to a rise in their serum creatinine (at which point damage to the kidney has already occurred), without having to perform a risky invasive protocol biopsy.

Daniel R Salomon

“The promise of precision medicine will only be achieved when molecular diagnostics detect actionable differences operating in individual patients, that can inform management and change clinical outcomes.”

Daniel R. Salomon 1953-2016